Sumitomo Mitsui Trust Group Inc. Has $322,000 Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Sumitomo Mitsui Trust Group Inc. lessened its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 98.3% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,141 shares of the medical research company's stock after selling 122,956 shares during the period. Sumitomo Mitsui Trust Group Inc.'s holdings in Charles River Laboratories International were worth $322,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of CRL. D1 Capital Partners L.P. bought a new stake in Charles River Laboratories International during the fourth quarter worth about $172,752,000. Assenagon Asset Management S.A. raised its holdings in Charles River Laboratories International by 1,721.1% during the first quarter. Assenagon Asset Management S.A. now owns 570,097 shares of the medical research company's stock worth $85,811,000 after acquiring an additional 538,792 shares in the last quarter. Norges Bank bought a new stake in Charles River Laboratories International during the fourth quarter worth about $98,886,000. Wellington Management Group LLP raised its holdings in Charles River Laboratories International by 9.0% during the fourth quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock worth $752,508,000 after acquiring an additional 335,658 shares in the last quarter. Finally, Nomura Holdings Inc. acquired a new position in Charles River Laboratories International during the fourth quarter worth approximately $56,820,000. Institutional investors own 98.91% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Robert W. Baird boosted their price target on Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a research report on Thursday, May 8th. TD Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price target on the stock in a research report on Wednesday, May 14th. Barclays boosted their price target on Charles River Laboratories International from $145.00 to $155.00 and gave the stock an "equal weight" rating in a research report on Thursday, May 8th. The Goldman Sachs Group downgraded Charles River Laboratories International from a "buy" rating to a "neutral" rating and decreased their target price for the company from $190.00 to $170.00 in a research report on Friday, March 21st. Finally, Wall Street Zen downgraded Charles River Laboratories International from a "buy" rating to a "hold" rating in a research report on Saturday. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $171.85.

Insiders Place Their Bets

In related news, EVP Joseph W. Laplume sold 500 shares of the stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the sale, the executive vice president directly owned 19,513 shares in the company, valued at $2,837,385.33. This represents a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Price Performance

NYSE CRL traded down $0.37 on Friday, hitting $157.12. 247,085 shares of the company's stock were exchanged, compared to its average volume of 1,029,147. The stock has a 50-day moving average of $140.70 and a 200-day moving average of $152.50. The company has a current ratio of 1.43, a quick ratio of 1.16 and a debt-to-equity ratio of 0.78. Charles River Laboratories International, Inc. has a 52 week low of $91.86 and a 52 week high of $254.15. The stock has a market cap of $7.72 billion, a price-to-earnings ratio of -241.72, a P/E/G ratio of 5.32 and a beta of 1.49.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, beating analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a positive return on equity of 15.19% and a negative net margin of 0.66%. The company had revenue of $984.17 million during the quarter, compared to analysts' expectations of $942.34 million. During the same period in the prior year, the company earned $2.27 EPS. Charles River Laboratories International's revenue was down 2.7% compared to the same quarter last year. Analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).